查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1517645

孟鲁司特钠市场 - 按产品类型（无定形孟鲁司特钠、结晶孟鲁司特钠）剂型（片剂、口服溶液）、应用（气喘、过敏性鼻炎、荨麻疹）、配销通路-全球预测（2024 - 2032）

Montelukast Sodium Market - By Product Type (Montelukast Sodium Amorphous, Montelukast Sodium Crystalline) Dosage Form (Tablets, Oral Solutions), Application (Asthma, Allergic Rhinitis, Urticaria), Distribution Channel - Global Forecast (2024 - 2032)
出版日期: | 出版商: Global Market Insights Inc. | 英文 190 Pages | 商品交期: 2-3个工作天内

价格
简介目录

由于全球气喘和过敏性鼻炎等呼吸系统疾病盛行率不断上升，孟鲁司特钠市场规模预计 2024 年至 2032 年复合年增长率为 11.4%。根据美国国立卫生研究院的数据，全球约有 4 亿人受到过敏性鼻炎的影响。

污染的增加和​​生活方式的改变导致人们越来越多地使用呼吸系统药物来改善症状。此外，研究人员正在发现治疗慢性阻塞性肺病和支气管炎等呼吸道疾病的药物的新用途，从而导致产品需求增加。製药公司和研究机构之间的合作也推动了市场的成长。

孟鲁司特钠产业按产品类型、剂型、应用、配销通路和地区细分。

就剂型而言，由于口服溶液的便利性、易于给药和增强的患者依从性，预计到 2032 年，口服溶液领域的市场规模将大幅成长。以患者为中心的医疗保健强调口服溶液作为片剂或颗粒剂的替代品，特别是对于儿童和老年人，为吞嚥困难的人提供精确的剂量控制。口服溶液还可以提供更好的口味，并提高患者在医疗保健环境中的接受度和依从性。

过敏性鼻炎应用领域的孟鲁司特钠产业将在 2024 年至 2032 年期间产生可观的收入，这得益于药物在管理呼吸系统疾病相关症状方面的效率。过敏性鼻炎是一种常见疾病，会导致鼻塞、打喷嚏和眼睛发痒等症状。为此，使用孟鲁司特钠，因为它针对白三烯来缓解症状并改善患者的呼吸健康。

由于环境污染、生活方式改变和遗传倾向导致呼吸系统疾病盛行率上升，亚太地区孟鲁司特钠产业预计到 2032 年将显着增长。亚洲的城市成长和工业扩张正在恶化空气品质。政府对改善卫生基础设施和扩大药物取得的支持不断增加也将刺激区域市场的成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 呼吸道疾病盛行率增加
      • 药物输送的进展
      • 提高认识和诊断
    • 产业陷阱与挑战
      • 副作用和安全问题
      • 替代治疗方案
  • 成长潜力分析
  • 监管环境
  • 波特的分析
  • 佩斯特尔分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 竞争定位矩阵
  • 战略展望矩阵

第 5 章：市场估计与预测：按产品类型，2021 - 2032 年

  • 主要趋势
  • 无定形孟鲁司特钠
  • 孟鲁司特钠结晶

第 6 章：市场估计与预测：按剂型，2021 - 2032

  • 主要趋势
  • 平板电脑
  • 口服溶液

第 7 章：市场估计与预测：按应用分类，2021 - 2032

  • 主要趋势
  • 气喘
  • 过敏性鼻炎
  • 荨麻疹
  • 其他应用

第 8 章：市场估计与预测：按配销通路划分，2021 - 2032 年

  • 主要趋势
  • 医院药房
  • 零售药局
  • 网路药局

第 9 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿联酋
    • 中东和非洲其他地区

第 10 章：公司简介

  • Apotex Inc.
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Intas Pharmaceuticals Ltd
  • Merck & Co., Inc.
  • Morepen Laboratories Limited
  • Mylan N.V.
  • Sandoz AG
  • Sanofi
  • Sun Pharma Industries Limited.
  • Teva Pharmaceutical Industries Limited
简介目录
Product Code: 9309

Montelukast sodium market size is estimated to register 11.4% CAGR between 2024 and 2032, backed by the rising prevalence of respiratory diseases, such as asthma and allergic rhinitis worldwide. As per the National Institute of Health, around 400 million people globally are affected with allergic rhinitis worldwide.

Increased pollution and changing lifestyles are leading to the increased use of respiratory medications to improve symptoms. Moreover, researchers are uncovering new uses for drugs in treating respiratory diseases likes COPD and bronchitis, leading to increased product demand. Collaborations between pharmaceutical companies and research institutes are also driving the market growth.

The montelukast sodium industry is segmented into product type, dosage form, application, distribution channel and region.

With respect to dosage form, the market size from the oral solutions segment is anticipated to witness substantial growth through 2032, owing to their convenience, ease of administration, and enhanced patient compliance. Patient-centered healthcare is emphasizing oral solutions as an alternative to tablets or granules, particularly for children and the elderly for offering precise dose control for those who have difficulty swallowing. Oral solutions also provide better taste as well as increased patient acceptance and compliance in healthcare settings.

Montelukast sodium industry from the allergic rhinitis application segment will generate notable revenue during 2024-2032, backed by the efficiency of drugs in managing symptoms related to respiratory conditions. Allergic rhinitis is a common condition causing symptoms like nasal congestion, sneezing, and itchy eyes. To that end, montelukast sodium is used as it targets leukotrienes to relieve symptoms and improve respiratory health for sufferers.

Asia Pacific montelukast sodium industry is slated to witness a significant growth rate through 2032, attributed to the rising prevalence of respiratory diseases due to environmental pollution, changing lifestyles, and genetic predispositions. Urban growth and industrial expansion in Asia are deteriorating air quality. The growing government support for improving health infrastructure and expanding access to medication will also stimulate the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360-degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of respiratory diseases
      • 3.2.1.2 Advancements in drug delivery
      • 3.2.1.3 Growing awareness and diagnosis
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Side effects and safety concerns
      • 3.2.2.2 Alternative treatment options
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Porter's analysis
  • 3.6 Pestel analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Competitive positioning matrix
  • 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Montelukast sodium amorphous
  • 5.3 Montelukast sodium crystalline

Chapter 6 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Tablets
  • 6.3 Oral solutions

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Asthma
  • 7.3 Allergic rhinitis
  • 7.4 Urticaria
  • 7.5 Other applications

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospital pharmacies
  • 8.3 Retail pharmacies
  • 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East And Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 South Africa
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Apotex Inc.
  • 10.2 Cipla Limited
  • 10.3 Dr. Reddy's Laboratories Ltd.
  • 10.4 Intas Pharmaceuticals Ltd
  • 10.5 Merck & Co., Inc.
  • 10.6 Morepen Laboratories Limited
  • 10.7 Mylan N.V.
  • 10.8 Sandoz AG
  • 10.9 Sanofi
  • 10.10 Sun Pharma Industries Limited.
  • 10.11 Teva Pharmaceutical Industries Limited